What the FDA labels say about taking them together
Nirmatrelvir/ritonavir and upadacitinib
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names upadacitinib in its drug interactions section; the upadacitinib label PlainMeds reads does not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “Drug Class: upadacitinib; Drugs within Class: ↑ upadacitinib; Effect on Concentration: Dosing recommendations for co-administration of upadacitinib with PAXLOVID depends on the upadacitinib indication. …”
Check it at the source: the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc); the upadacitinib FDA label on DailyMed (effective June 30, 2026, AbbVie Inc.).
What does the nirmatrelvir/ritonavir label say about upadacitinib?
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: upadacitinib; Drugs within Class: ↑ upadacitinib; Effect on Concentration: Dosing recommendations for co-administration of upadacitinib with PAXLOVID depends on the upadacitinib indication. Refer to the upadacitinib prescribing information for more information.
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
What does the upadacitinib label say about nirmatrelvir/ritonavir?
Upadacitinib's label (effective June 30, 2026) does not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Rinvoq), AbbVie Inc., effective June 30, 2026 (SPL set 2966aec7-2ef0-923c-d8ff-fe1a957bf095), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nirmatrelvir/ritonavir | Upadacitinib | |
|---|---|---|
| Labeled for | COVID-19 | Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $49.24 per unit 300-100 mg dose pack | $229.31 per tablet 15 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once